Compare Funko Inc (FNKO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Zimmer Biomet Holdings Inc — how do they compare? Funko Inc trades at $6.47 (market cap $363.97M), while Zimmer Biomet Holdings Inc trades at $89.49 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 46.6× Funko Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Funko Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FNKO | ZBH | |
|---|---|---|
Market Cap | $363.97M | $16.95B |
Volume | 1,422,651 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $103.98 |
52-Week Low | $2.81 | $79.58 |
Typical Hold Time | 33 Days | 89 Days |
Enterprise Value | $584.62M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.525, up 3.41% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue declined to $908.21M in 2025, but Q2 2026 results showed 7% sales growth and improved EBITDA margins. The company maintains a low P/S ratio of 0.38 and reduced debt, while analyst consensus is a 'Hold' with a $7.58 price target.
The outlook is cautiously optimistic; valuation appears attractive, but negative net income and volatile cash flows pose risks. Upside depends on sustained EBITDA growth and execution of the 'Make Culture POP' strategy, while competitive pressures and consumer spending trends remain key watchpoints for investors.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
